Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell lung cancer: the randomized PERLA phase II trial

PERLA is a global, double-blind, parallel phase II trial (NCT04581824) comparing efficacy and safety of anti–PD-1 antibodies dostarlimab and pembrolizumab, plus chemotherapy (DCT and PCT, respectively) as first-line treatment in patients with metastatic non-squamous NSCLC without known targetable ge...

Descripción completa

Detalles Bibliográficos
Autores principales: Lim, Sun Min, Peters, Solange, Ortega Granados, Ana Laura, Pinto, Gustavo dix Junqueira, Fuentes, Christian Sebastián, Lo Russo, Giuseppe, Schenker, Michael, Ahn, Jin Seok, Reck, Martin, Szijgyarto, Zsolt, Huseinovic, Neda, Zografos, Eleftherios, Buss, Elena, Stjepanovic, Neda, O’Donnell, Sean, de Marinis, Filippo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10640551/
https://www.ncbi.nlm.nih.gov/pubmed/37951954
http://dx.doi.org/10.1038/s41467-023-42900-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10640551/
https://www.ncbi.nlm.nih.gov/pubmed/37951954
http://dx.doi.org/10.1038/s41467-023-42900-4

Ejemplares similares